Recent progress in TGF-β inhibitors for cancer therapy

Biomedicine & Pharmacotherapy

Chun-Lin Chen¹  Chih-Ling Chung²  Tsung-Hui Hu³  Cheng-Yi Huang³  Jih-Jung Chen⁴  Pei-Feng Liu⁵ 

[1] Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan;Department of Pathology, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan, ROC;Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan, ROC;Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan, ROC;Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming University, Taipei 11221, Taiwan, ROC;

关键词: Small-molecule inhibitor;    Cancer therapy;    TGF-β inhibitor;    Endocytosis;    Lipid raft;   

DOI  :  

来源: DOAJ

【 摘 要 】

Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.

【 授权许可】

Unknown